Arbutus Biopharma Corp (ABUS)
2.71
+0.03
(+1.12%)
USD |
NASDAQ |
May 03, 16:00
2.715
0.00 (0.00%)
After-Hours: 20:00
Arbutus Biopharma Research and Development Expense (Quarterly): 17.56M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.56M |
| September 30, 2023 | 20.17M |
| June 30, 2023 | 17.69M |
| March 31, 2023 | 18.28M |
| December 31, 2022 | 22.95M |
| September 30, 2022 | 20.06M |
| June 30, 2022 | 22.94M |
| March 31, 2022 | 18.46M |
| December 31, 2021 | 19.21M |
| September 30, 2021 | 16.71M |
| June 30, 2021 | 15.80M |
| March 31, 2021 | 13.78M |
| December 31, 2020 | 16.39M |
| September 30, 2020 | 12.06M |
| June 30, 2020 | 10.46M |
| March 31, 2020 | 10.42M |
| December 31, 2019 | 12.42M |
| September 30, 2019 | 17.73M |
| June 30, 2019 | 12.74M |
| March 31, 2019 | 14.71M |
| December 31, 2018 | 11.06M |
| September 30, 2018 | 16.57M |
| June 30, 2018 | 16.36M |
| March 31, 2018 | 13.95M |
| December 31, 2017 | 17.82M |
| Date | Value |
|---|---|
| September 30, 2017 | 15.54M |
| June 30, 2017 | 15.44M |
| March 31, 2017 | 13.87M |
| December 31, 2016 | 17.16M |
| September 30, 2016 | 15.74M |
| June 30, 2016 | 15.22M |
| March 31, 2016 | 13.14M |
| December 31, 2015 | 14.90M |
| September 30, 2015 | 16.35M |
| June 30, 2015 | 9.69M |
| March 31, 2015 | 10.56M |
| December 31, 2014 | 11.90M |
| September 30, 2014 | 9.309M |
| June 30, 2014 | 9.298M |
| March 31, 2014 | 8.204M |
| December 31, 2013 | 6.971M |
| September 30, 2013 | 5.506M |
| June 30, 2013 | 4.914M |
| March 31, 2013 | 4.067M |
| December 31, 2012 | 7.059M |
| September 30, 2012 | 3.152M |
| June 30, 2012 | 3.512M |
| March 31, 2012 | 4.146M |
| December 31, 2011 | |
| September 30, 2011 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
10.42M
Minimum
Mar 2020
22.95M
Maximum
Dec 2022
16.62M
Average
17.56M
Median
Dec 2023
Research and Development Expense (Quarterly) Benchmarks
| Moderna Inc | 1.063B |
| Pacira BioSciences Inc | 19.46M |
| Chimerix Inc | 15.64M |
| Karyopharm Therapeutics Inc | 39.38M |
| Corvus Pharmaceuticals Inc | 3.999M |